首页> 外文会议>第二届全国分子模拟与信息技术软件应用研讨会暨第四届创腾科技用户大会 >The difference of binding epitopes on human CD16 (FcγRIII) interacted with hIgG1 and monoclonal antibody B88-9
【24h】

The difference of binding epitopes on human CD16 (FcγRIII) interacted with hIgG1 and monoclonal antibody B88-9

机译:人CD16(FcγRIII)上结合表位的差异与hIgG1和单克隆抗体B88-9相互作用

获取原文

摘要

The 3-D complex structures of extracellular domain of human CD16 (FcγRIII) and hIgG1 or B88-9 were obtained by means of computer-guided molecular modeling, respectively. The binding epitopes were predicted and binding energy was calculated theoretically. The epitopes of human CD16 interacted with hIgG1 and B88-9 were different and the binding energy of B88-9 was stronger than hIgG1. The computer competing simulation results showed that B88-9 could bind to CD16 when CD16 was also bound by hIgG1, while IgG1 could not bind to CD16 after CD16 was bound by B88-9. By flow cytometry analysis, the competitive binding activity of B88-9 to CD16 with hIG1 was evaluated. With the increasing concentrations of hIgG1, the binding activity of B88-9 was not interfered markedly. It suggested that hIgG1 could not inhibit the interaction of CD16 and B88-9 and the binding domain of hIgG1 and B88-9 on CD16 was different.
机译:人CD16(FcγRIII)和hIgG1或B88-9的胞外域的3-D复杂结构分别通过计算机指导的分子建模获得。预测结合表位,并从理论上计算结合能。与hIgG1和B88-9相互作用的人CD16的表位不同,B88-9的结合能强于hIgG1。计算机竞争模拟结果表明,当h16g1也与CD16结合时,B88-9可以与CD16结合,而当b8-9结合CD16后,IgG1不能与CD16结合。通过流式细胞术分析,评估了b88-9与hIG1对CD16的竞争结合活性。随着hIgG1浓度的增加,B88-9的结合活性不会受到明显干扰。提示hIgG1不能抑制CD16与B88-9的相互作用,hIgG1与B88-9在CD16上的结合域不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号